Kathleen G. Essel, MD, discusses the role of quantitative imaging feature analysis in gynecologic cancers.
Kathleen G. Essel, MD, a fellow at The University of Oklahoma Stephenson Cancer Center, discusses the role of quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in gynecologic cancers.
This is a new technology that identifies whether or not a patient will respond to treatment based on tumor imaging and RECIST criteria, says Essel. A computer detection scheme can determine which different features are present or absent, then make a score for patient response.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More